Skip to content

Clinical study of the safety and efficacy of COLTRIX® CartiRegen collagen repair scaffold for the prevention of recurrent intrauterine adhesion

Clinical study of the safety and efficacy of COLTRIX® CartiRegen collagen repair scaffold for the prevention of recurrent intrauterine adhesion - Clinical study of the safety and efficacy of COLTRIX® CartiRegen collagen repair scaffold for the prevention of recurrent intrauterine adhesion

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090735
Enrollment
Unknown
Registered
2024-10-12
Start date
2024-10-31
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to severe intrauterine adhesions

Interventions

Experimental group:COLTRIX? CartiRegen collagen cartilage repair scaffold
Control group:Crosslinked sodium hyaluronate gel for uterine cavity

Sponsors

Hospital of Obstetrics and Gynecology affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1) The subjects were aged 18-40 years old (including 18 and 40 years old), female; 2) Patients diagnosed with moderate to severe uterine adhesions by hysteroscopy (AFS score =5); 3) Have not participated in other clinical investigators within 3 months; 4) The subjects fully understood the benefits and risks of this study and were still willing to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1) mild intrauterine adhesions; 2) only intrauterine oral adhesion; 3) Malignant tumor; 4) Irregular vaginal bleeding for unknown reasons; 5) There are contraindications to pregnancy; 6) Patients with contraindications to hysteroscopy; 7) People who have a special belief that they cannot receive the product (the product source is pig), allergies, such as pig protein allergy, a history of autoimmune disease or a family history; 8) Other researchers believe that the candidates are not suitable for admission, such as the efficacy can not be evaluated.

Design outcomes

Primary

MeasureTime frame
AFS score ;

Secondary

MeasureTime frame
Incidence of uterine readhesion (%);Endometrial thickness;menstruation;Efficacy evaluation;Pregnancy outcome;

Countries

China

Contacts

Public Contactsui long

Hospital of Obstetrics and Gynecology affiliated to Fudan University

suilong@sh163.net+86 153 5682 9160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026